ABSTRACT
exists as to whether continued cognitive impairment following HAART represents an active process, the impact of comorbidities, or pre-HAART brain injury.
In its pure, untreated form, HIV encephalitis is characterized by CNS immune activation with perivascular macrophage accumulation. 6 It is theorized that CNS injury occurs when monocytes, many of which are infected, transmigrate the blood-brain barrier, resulting in an inflammatory response in the absence of substantial neuronal apoptosis. [7] [8] [9] [10] This pathway has been described in animal models of lentivirus infection. 11, 12 In some animal models, monocyte tissue transmigration appears to trigger gene expression of otherwise quiescent virus, raising the possibility that harboring virus in peripheral monocytes, even when not actively productive, may have clinical consequences upon tissue infiltration. 13 In this prospective study, we evaluated early immunologic, virologic, and neurocognitive changes with initiation of first-time HAART to clarify the neuropathogenesis of NCI in HAART-treated individuals. We previously reported a correlation between peripheral blood mononuclear cell (PBMC) HIV DNA and NCI in HAART-naïve patients from this cohort. 14 We now identify this relationship specific to circulating monocytes (CD14 ϩ cells) and describe the longitudinal relationship between this marker and cognitive recovery.
METHODS Patient selection. SEARCH 001 enrolled 15
patients with HIV with HAD and 15 without HAD, all confirmed to be infected with HIV-1 circulating recombinant form (CRF) 01_AE. Groups were matched by age, gender, CD4 lymphocyte count, and educational attainment, as previously described. 15 Briefly, individuals were identified from infectious disease clinics, neurology clinics, and HIV testing facilities in Bangkok and were eligible for enrollment if they met Thai national guidelines to initiate HAART and intended to start treatment. All assessments were completed within 1 month before first dose of antiretroviral (ARV) therapy. Participants were hepatitis C antibody negative, denied illicit drug use, lacked factors that would potentially impact cognition (e.g., head injury, learning disability), and had two negative urine toxicology screens on separate days. Normative neuropsychological data were obtained from 230 age-and education-matched HIVnegative Thai controls who denied confounds that could impact cognition (e.g., head injury, medical illness, learning disability, illicit drug use), had a normal screening neurologic examination, were tested to be HIV (EIA) negative, and had a negative urine drug screen.
Cognitive characterization. Dementia was determined by a trained neurologist (P.S.) using standard-of-care assessments in Thailand, which included a comprehensive neurologic examination, simple bedside cognitive testing including the International HIV Dementia Scale (IHDS), patient and proxy reporting of symptoms, and brain MRI. When clinically indicated, lumbar puncture was completed. We employed the neuropsychological testing battery modified from an international HIV battery previously used in Bangkok and designed to minimize cultural influences. 16, 17 Testing was completed by trained nursepsychometrists with quality assurance review every 6 months.
Cell separation. Peripheral blood mononuclear cells were treated with Accumax (Innovative Cell Technologies, San Diego, CA) to prevent cell clumping. Cells were then washed with RoboSep buffer (Stemcell Technologies, San Diego, CA; PBS, 2% FBS, 1 mM EDTA); counted; centrifuged; and resuspended. Monocyte separation was performed using the monocyte separation kit (Stemcell Technologies). Magnetic bead separation identified monocytes (CD14-positive) and non-monocytes (CD14-negative) fractions, which were then stored at Ϫ80°C before HIV DNA analyses.
Proviral HIV DNA assessments. PBMCs were shipped to the University of Hawaii in frozen batches where we isolated DNA from the cells per manufacturer's instructions (Qiagen, Inc., Valencia, CA) and measured HIV DNA copies. 18 Briefly, we generated standard curves for the real-time PCR assays from dilutions of a plasmid containing one HIV copy (GenBank accession #NC_001802) and one copy of the human housekeeping gene, ␤-globin (GenBank accession #2253431). Reactions were prepared with 100 ng of the sample DNA; HIV gag primers or ␤-globin primers; 1x iQ supermix (BioRad Laboratories, Hercules, CA); and water to final volume 25 L. Initial denaturation was performed for 3 minutes followed by 45 cycles of two-step PCR 95°C/10 seconds, 57°C/30 seconds, and a final extension of 72°C/2 minutes. Controls were a negative control (no DNA template) and DNA from three HIV-infected cell lines (8E5, OM10.1, ACH-2, NIH AIDS Research and Reference Reagent Program, Rockville, MD), which were also used for interassay calibration. Assays were completed on PBMCs (not monocyte depleted) and monocytes (CD14ϩ cells) and operators were blinded to HAD status.
Summary neuropsychological measures.
Neuropsychological z-scores were calculated by standard methodology compared to appropriate age and educational attainment strata from the normative data. Our initial longitudinal cognitive endpoints were the global deficit score (GDS), a weighted summary of all neuropsychological z-scores, 19 where a higher GDS represents greater impairment and a global nonweighted summary z-score of all tests in our battery (NPZglobal). Preliminary analyses revealed nonsignificant differences between HAD and non-HAD groups on these measures, despite differences noted in many individuals' cognitive tests (appendix e-1 on the Neurology ® Web site at www.neurology.org). We therefore formulated a third composite score (NPZcomp) in a post hoc manner. This was accomplished by contrasting performance characteristics of individual test by HAD/non-HAD group, retaining those at p Ͻ 0.10, with final selection for those with the largest and most meaningful differences: RAVLT-total of trials 1-5 (learning efficiency), digit symbol modalities task (psychomotor speed), and timed gait (motor speed). A discriminant analysis with cross validation (PROC DISCRIM, SAS) confirmed that the NPZcomp correctly categorized 21/30 (70%) cases as HAD/non-HAD at baseline. We then completed external validation of the NPZcomp in a separate cohort (Hawaii Aging with HIV Cohort, n ϭ 286) 4 where the NPZcomp accurately categorized 79% of cases (186/198 non-HAD and 48/88 HAD).
Informed consent and statistical analyses. The protocol was approved by the Ethical Review Committees at Phramongkutklao Medical Center, the Walter Reed Army Institute of Research, and the University of Hawaii. All participants signed informed consent. All cases (HAD and non-HAD) were pooled and we employed normal linear regression models to determine the relationship between independent variables and neuropsychological summary scores. All summary scores met model requirements, although the GDS required logarithmic transformation. To take into account within-subject variability, longitudinal mixed normal models were used to assess the effects of baseline levels and subsequent changes in predictive variables (PROC MIXED). In fitting the mixed models, the three cognitive response factors were separately analyzed and correlation of these variables within subjects was assumed to be normally distributed. We employed compound symmetry for our covariance structure, which provided a better fit compared to an unstructured covariance matrix, as assessed by likelihood ratio test. Unless otherwise stated, HIV DNA in the results represents that measured in monocytes.
RESULTS Baseline immunologic and virologic factors. SEARCH 001 enrolled 30 individuals and 29 initiated HAART. One case was lost to follow-up and one died before 48 weeks (both in the HAD group). Our analysis included 27 cases with 48-week data available (12 HAD and 15 non-HAD). Factors that distinguished HAD from non-HAD included higher Thai Depression Inventory score (TDI), lower hemoglobin, and higher intracellular PBMC HIV DNA, as previously reported. 14, 15 The relationship between baseline log 10 HIV DNA and HAD remained present when analyzed among the CD14-positive subset (monocytes, p Ͻ 0.001). Plasma HIV RNA level and CD4 lymphocyte count did not correlate to HAD; however, all participants had low CD4 counts (table 1) . The NPZcomp summary score (p ϭ 0.002) and the IHDS (p Ͻ 0.001) each differed significantly by HAD status. Baseline monocyte HIV DNA correlated to NPZcomp score, but did not meet significance when analyzed for the GDS or NPZglobal measures. The relationship between monocyte HIV DNA and the NPZcomp remained significant after adjustment for plasma HIV RNA and CD4 count (␤ ϭ Ϫ0.253, SE ϭ 0.059, p Ͻ 0.001, figure 1 ).
48-Week immunologic and virologic response to
HAART. One participant's ARV regimen was not known due to coenrollment in a second study which provided HAART in a blinded fashion. All others initiated NNRTI-based ARV with most (21/26) starting nevirapine-based ARV. Among these cases, the NRTI backbone for most (24/26) was stavudine and lamivudine, using GPOvir (fixed-dose combina- DISCUSSION This report confirms cognitive improvement with HAART among individuals from Southeast Asia and, specifically, among individuals known to be infected with HIV-1 CRF 01_AE. This finding complements our understanding of cognitive improvement in subtype B infected individuals 20 and more recent reports among patients presumed to be infected with subtypes A and D in Africa. 21 We also report that HIV DNA isolated specifically from circulating monocytes correlates to HAD in HAARTnaïve individuals. In this cohort, having a monocyte HIV DNA level exceeding 3.5 log 10 copies/10 6 cells identified all HAD and excluded all non-HAD cases, indicating 100% sensitivity and specificity for HAD in this small cohort. Monocyte HIV DNA also relates to cognition 48 weeks post HAART, and, while less clear, baseline monocyte HIV DNA may predict short-term (48-week) cognitive response to HAART. This finding is more notable in light of our previous work with this cohort, which failed to identify the cell surface activation markers CD14 ϩ /16 ϩ as predictive of HAD. 22 The lack of correlation between our a priori cognitive measures (GDS and NPZglobal scores) and HAD at baseline was unexpected and is likely due to the small sample size and diminished sensitivity inherent in pooling measures. We cannot rule out the potential influence of selection bias associated with the tools used to diagnose HAD. Cultural influences could be a factor despite choosing a battery designed to minimize such bias. 23 Consequently, our certainty regarding the impact of HIV DNA on cognitive improvement is diminished since we required development of the NPZcomp measure in a post hoc manner. Nevertheless, the NPZcomp was designed using robust statistical models to capture HAD status at baseline in this cohort, was validated externally, and represents cognitive tests with validity in HIV. We note that the performance of our non-HAD subjects increased to a level higher than our HIVnegative controls by week 48. We suspect this reflects a learning effect on our cognitive testing battery, as longitudinal control data are not yet available. Learning effects can confound analyses of longitudinal data; however, in this case, the impact would limit our ability to demonstrate continued impairment. Consequently, the 48-week cognitive data may underestimate the lack of improvement in HAD cases.
Our findings extend our knowledge of HAD in HAART-treated individuals by noting an incomplete cognitive recovery in some individuals at 48 weeks and suggesting that this incomplete recovery may in part be an active process. 2, 4, 24 While HAART suppresses plasma HIV RNA in most individuals and induces immunologic recovery, treatment does not eradicate virus within reservoirs, such as mono- cytes. 25, 26 In our cohort, only four HAD cases but all non-HAD cases decreased monocyte HIV DNA levels to below that detectable by our assay (10 copies/ 10 6 cells) at 48 weeks. The extent to which longer duration of treatment with HAART will further diminish this reservoir is not yet known, but is expected based on published work. 27 Full clearance may not occur in all individuals with typical HAART based on our previous cross-sectional work where patients with HAD, many of whom had been on stable HAART for years and with undetectable plasma HIV RNA, were more likely to have elevated PBMC HIV DNA. 28 The accumulated evidence suggests that monocyte HIV DNA plays a role in HIV neuropathogenesis and raises the possibility that, in some patients, incomplete cognitive recovery with HAART may be an active process associated with this peripheral reservoir. Previously described fluctuation in cognition also supports an active process, 3, 29 although comorbidity may account for some of this fluctuation. Comorbidity would less likely explain variability in our cohort as individuals were meticulously screened for confounding factors and highly adherent to ARV. Most were young and none had brain opportunistic infection or hepatitis C. All denied illicit drug use and were tested negative twice by urine toxicology screen. In our cohort, the mean TDI scores were higher in HAD cases; however, all cases of major depression were excluded. Nevertheless, depressive symptoms must be considered to potentially impact our assessments. The overlap between the symptoms of HAD (slowed responses, flat affect, and apathy) and depressive symptoms is well described. 4, 30 Our findings are consistent with existing models of monocyte transmigration resulting in CNS infection and inflammation. 9, 31, 32 They are also congruent with reports that HIV DNA influences HIV disease progression. For example, elevated HIV DNA was reportedly predictive of poor response to antiretroviral therapy in early studies 33 and of patients who experienced virologic failure in another study. 34 HIV DNA predicts progression to AIDS in the SEROCO cohort study in Europe, independently of plasma HIV RNA and CD4 counts, 35 and in the PRIMO Cohort, where patients are enrolled at the time of primary HIV infection. 36 In our work, it is not clear if HIV DNA in circulating monocytes exhibits its effects through elevation of CSF HIV RNA; however, one patient with elevated 48-week PBMC HIV DNA and cognitive impairment had undetectable CSF HIV RNA (limit of detection, 50 copies/mL). We predict that this marker's impact is independent of CSF HIV RNA.
